Remogliflozin etabonate
From Wikipedia, the free encyclopedia
Systematic (IUPAC) name | |
---|---|
5-methyl-4-[4-(1-methylethoxy)benzyl]-1-(1-methylethyl)-1H-pyrazol-3-yl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside | |
Clinical data | |
Legal status | ? |
Routes | Oral |
Identifiers | |
CAS number | 442201-24-3 |
ATC code | None |
UNII | TR0QT6QSUL |
KEGG | D10055 |
ChEMBL | CHEMBL494323 |
Chemical data | |
Formula | C26H38N2O9 |
Mol. mass | 522.586 g/mol |
SMILES
| |
(what is this?) (verify) | |
Remogliflozin etabonate (INN/USAN)[1] is a proposed drug for the treatment of type 2 diabetes being investigated by GlaxoSmithKline.[2] Remogliflozin is now being developed by BHV Pharma.[citation needed]
Method of action
Remogliflozin inhibits the sodium-glucose transport proteins, which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.[3]
References
- ↑ Statement on a nonproprietory name adopted by the USAN council
- ↑ Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M (June 2008). "Remogliflozin etabonate, in a Novel Category of Selective Low-Affinity / High-Capacity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models". J. Pharmacol. Exp. Ther. 327 (1): 268–276. doi:10.1124/jpet.108.140210. PMID 18583547.
- ↑ Prous Science: Molecule of the Month November 2007
|
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.